NCT00790218View on ClinicalTrials.gov

A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2013

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

CF102

CF102 capsules twice daily by mouth

Trial Locations (1)

Unknown

Rabin Medical Center, Tel Aviv

Sponsors

Lead Sponsor

Can-Fite BioPharma
All Listed Sponsors
lead

Can-Fite BioPharma

INDUSTRY